文献速递生殖医学妇科

癌症治疗对多囊卵巢综合征女性不孕风险及卵巢储备下降的影响

Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome.
PubMed 文献 · Fertil Steril · 2018-02-07

基于人群的队列研究(FUCHSIA女性研究)纳入1,090例22-45岁女性癌症幸存者及374例无癌女性,比较伴或不伴多囊卵巢综合征(PCOS)者的不孕、生育目标及卵巢储备指标。伴PCOS的幸存者接受或未接受性腺毒性治疗后报告不孕的比值比分别为2.3和3.4,且更少达到 desired 子女数;调整年龄后,无癌PCOS女性卵巢储备标志物最高,接受性腺毒性治疗的无PCOS幸存者最低。

要点

  • 伴PCOS的癌症幸存者接受性腺毒性治疗后报告不孕的OR为2.3(95%CI 1.2-4.5),未暴露者为3.4(95%CI 1.7-6.9)。
  • 伴PCOS幸存者更可能子女数少于期望(暴露OR 2.1,95%CI 1.0-4.2;未暴露OR 3.0,95%CI 1.4-6.8)。
  • 调整年龄后,无癌PCOS女性AMH 2.43 ng/mL、AFC 20.7最高,接受性腺毒性治疗的无PCOS幸存者AMH 0.19 ng/mL、AFC 7.4最低。

核心结论

  • 尽管癌症治疗后伴PCOS的幸存者平均AMH和AFC较高,但与无PCOS的幸存者相比,她们更不可能实现其生殖目标。

研究设计与样本

  • FUCHSIA女性研究——基于人群的队列研究,纳入1,090例22-45岁、20-35岁确诊且确诊至少2年的女性癌症幸存者,其中369例完成门诊访视;374例无癌育龄女性也完成门诊访视。

主要发现

  • 78例癌症幸存者(7.2%)报告PCOS诊断,其中41例接受性腺毒性治疗。
  • 伴PCOS且接受性腺毒性治疗的幸存者报告不孕的OR为2.3(95%CI 1.2-4.5),未暴露者为3.4(95%CI 1.7-6.9),均高于未暴露且无PCOS的幸存者。
  • 伴PCOS幸存者更可能子女数少于期望(暴露OR 2.1,95%CI 1.0-4.2;未暴露OR 3.0,95%CI 1.4-6.8)。
  • 调整年龄后,无癌PCOS女性卵巢储备标志物最高(AMH 2.43 ng/mL,95%CI 1.22-4.82 ng/mL;AFC 20.7,95%CI 15.3-27.8)。
  • 接受性腺毒性治疗的无PCOS癌症幸存者卵巢储备标志物最低(AMH 0.19 ng/mL,95%CI 0.14-0.26 ng/mL;AFC 7.4,95%CI 6.4-8.5)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare markers of fertility and ovarian reserve between cancer survivors and cancer-free women with and without polycystic ovary syndrome (PCOS). DESIGN: Furthering Understanding of Cancer, Health, and Survivorship in Adult (FUCHSIA) Women's Study-a population-based cohort study. SETTING: Not applicable. PATIENT(S): Female cancer survivors (n = 1,090) aged 22-45 years, diagnosed between ages 20 and 35 years, and at least 2 years after diagnosis; 369 participated in a clinic visit. Three hundred seventy-four reproductive-aged women without cancer also completed a clinic visit. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Infertility, time to first pregnancy after cancer diagnosis, and measures of ovarian reserve (antimüllerian hormone [AMH] and antral follicle count [AFC]). RESULTS: Seventy-eight cancer survivors (7.2%) reported a PCOS diagnosis, with 41 receiving gonadotoxic treatment. Survivors with PCOS exposed to gonadotoxic treatment (odds ratio [OR] 2.3, 95% confidence interval [CI] 1.2-4.5) and unexposed (OR 3.4, 95% CI 1.7-6.9) were more likely to report infertility than unexposed survivors without PCOS and were more likely to have fewer children than desired (exposed: OR 2.1, 95% CI 1.0-4.2; unexposed: OR 3.0, 95% CI 1.4-6.8). After adjusting for age, comparison women with PCOS had the highest markers of ovarian reserve (AMH: 2.43 ng/mL, 95% CI 1.22-4.82 ng/mL; AFC: 20.7, 95% CI 15.3-27.8), and cancer survivors without PCOS treated with gonadotoxic agents had the lowest levels (AMH: 0.19 ng/mL, 95% CI 0.14-0.26 ng/mL; AFC: 7.4, 95% CI 6.4-8.5). CONCLUSION(S): Despite having higher AMH and AFC on average after cancer treatment, cancer survivors with PCOS were less likely to meet their reproductive goals compared with survivors without PCOS.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Shandley LM, Fothergill A, Spencer JB, et al. Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome. Fertil Steril. 2018. PMID: 29428311. doi:10.1016/j.fertnstert.2017.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。